First Bank & Trust Castle Biosciences Inc Transaction History

First Bank & Trust

$605 Million
Q4 2025

A detailed history of First Bank & Trust transactions in Castle Biosciences Inc stock. As of the latest transaction made, First Bank & Trust holds 16,706 shares of CSTL stock, worth $558,815. This represents 0.09% of its overall portfolio holdings.

Number of Shares

16,706

Previous 19,799 15.62%

Holding current value

$558,815

Previous $450,000 24.0%

% of portfolio

0.09%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 12, 2026	SELL	$22.14 - $34.97 $68,479 - $108,162	-3,093 Reduced 15.62%	16,706 $558,000
Q3 2025 Oct 10, 2025	SELL	$14.65 - $24.65 $2,226 - $3,746	-152 Reduced 0.76%	19,799 $450,000
Q2 2025 Jul 09, 2025	BUY	$15.8 - $21.98 $76,077 - $105,833	4,815 Added 31.81%	19,951 $407,000
Q1 2025 Apr 28, 2025	BUY	$18.76 - $32.72 $122,165 - $213,072	6,512 Added 75.51%	15,136 $303,000
Q4 2024 Feb 03, 2025	SELL	$26.52 - $34.67 $14,320 - $18,721	-540 Reduced 5.89%	8,624 $229,000

Q3 2024 Oct 24, 2024	BUY	$17.4 - $31.47 $159,453 - $288,391	9,164 New	9,164 $261,000
Q2 2022 Jul 22, 2022	BUY	$16.0 - $45.99 $59,328 - $170,530	3,708 Added 90.22%	7,818 $172,000
Q1 2022 Apr 29, 2022	BUY	$33.17 - $46.98 $24,313 - $34,436	733 Added 21.71%	4,110 $184,000
Q4 2021 Feb 01, 2022	BUY	$39.06 - $67.58 $91,556 - $158,407	2,344 Added 226.91%	3,377 $145,000
Q3 2021 Oct 18, 2021	BUY	$60.13 - $77.6 $36,619 - $47,258	609 Added 143.63%	1,033 $69,000
Q2 2021 Aug 10, 2021	BUY	$50.07 - $76.78 $21,229 - $32,554	424 New	424 $31,000

Others Institutions Holding CSTL

# of Institutions

185

Shares Held

27M

Call Options Held

42.2K

Put Options Held

9.3K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $880M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on First Bank & Trust with notifications on news.

Account